Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 110.00
Bid: 110.00
Ask: 110.80
Change: -0.60 (-0.54%)
Spread: 0.80 (0.727%)
Open: 110.20
High: 110.80
Low: 110.00
Prev. Close: 110.60
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks mixed; UK economic recovery slows

Wed, 22nd Dec 2021 09:12

(Alliance News) - Stock prices in London opened mixed on Wednesday amid concerns over the Omicron variant and government measures to contain it, while investors digested disappointing UK economic growth figures.

UK Prime Minister Boris Johnson on Tuesday gave the go-ahead for people's Christmas plans, although he warned tougher restrictions could be implemented post-December 25.

Johnson said "continuing uncertainty" about the severity of the Omicron variant and hospital admission rates means he does not believe there is enough evidence at the moment to justify stricter measures.

But the situation remains "finely balanced" and people should "exercise caution", Johnson added.

The FTSE 100 index was down 21.58 points, or 0.2%, at 7,275.83 early Wednesday. But the mid-cap FTSE 250 index was up 27.30 points, or 0.1%, at 22,847.60, and the AIM All-Share index was up marginally at 1,174.62.

The Cboe UK 100 index was down 0.2% at 722.37. The Cboe 250 was up 0.2% at 20,252.10, and the Cboe Small Companies was up 0.1% at 14,839.54.

In mainland Europe, the CAC 40 stock index in Paris was up 0.1%, while the DAX 40 in Frankfurt was 0.2% higher.

In Asia on Wednesday, the Nikkei 225 index in Tokyo closed up 0.2%. In China, the Shanghai Composite closed down 0.1%, and the Hang Seng index in Hong Kong ended up 0.6%. The S&P/ASX 200 in Sydney closed up 0.1%.

In the FTSE 100, Taylor Wimpey rose 0.3% after the UK Competition & Markets Authority ended its probe into the housebuilder over ground rents.

Taylor Wimpey said the CMA investigation into the historical sale of leasehold properties with doubling ground rent clauses by the company is closed, following the agreement of voluntary undertakings.

The housebuilder said the cost of the undertakings falls within the original provision Taylor Wimpey made in 2017. By entering into the undertakings there is no finding that Taylor Wimpey has infringed UK consumer law, it noted.

Conversely, Croda International was down 0.9%. The speciality chemicals company has agreed to sell the majority of its Performance Technologies and Industrial Chemicals businesses to Cargill for an enterprise value of EUR915 million on a cash-free, debt-free basis.

Croda said the disposal of the businesses follows the strategic review that it announced in May. The operations being sold represent 77% of PTIC's 2020 revenue and consist of five manufacturing facilities in the UK, China and the Netherlands.

Land Securities was down 0.1%. The property developer Land Securities bought a further stake in the Bluewater shopping mall outside London.

Landsec said it has completed the acquisition of an additional 25% share in Bluewater from Lendlease Retail Partnership for GBP172 million, representing a net initial yield of 8.15% and an equivalent yield of 8.25%.

In a separate deal, Landsec said it will sell 25% of this share - a 7.5% stake - to co-owner M&G for its pro rata share of the purchase price with the deal completing in April 2022. After this, Landsec's ownership of Bluewater will be 48.8%.

In the FTSE 250, Syncona was the best performer, up 8.5%, after the healthcare investor said its portfolio company Gyroscope Therapeutics will be sold to Swiss pharmaceutical company Novartis for up to USD1.5 billion.

Syncona has a 54% stake in Gyroscope following a USD42 million investment in March, after co-founding the business in 2016.

Novartis shares were down 0.3% in Zurich.

Pennon was down 0.3% after the CMA said the utility has until December 31 to give undertakings for its Bristol Water acquisition.

The regulator said the Pennon acquisition of Bristol Water may impede Ofwat's ability to make comparisons between water companies.

In response, Pennon said it intends to provide undertakings to CMA for Bristol Water by December 31.

The pound was quoted at USD1.3253 early Wednesday, up from USD1.3248 at the London equities close Tuesday, despite disappointing UK economic growth figures.

UK economic growth was revised lower in the third quarter on a quarterly basis but higher on an annual basis, figures from the Office for National Statistics showed.

On the quarter before, UK gross domestic product advanced by 1.1% in the three months to September, slower than a 5.4% rise in the three months to July, but missed consensus of an expansion of 1.3%, which would have matched the first estimate.

On a year before, the UK economy grew by 6.8% in the third quarter, slowing sharply from the 24% annual growth rate in the second quarter. The latest reading slightly beat the market forecast, cited by FXStreet, of 6.6% annual growth, which also would have matched the first estimate.

Analysts at Capital Economics said: "The downward revision to GDP in Q3 means the economy had a little less momentum going into the closing months of the year than we previously thought. And given early signs that the huge surge in Covid-19 infections has weighed on activity so far in December, GDP growth looks to have slowed in Q4.

"But these data are old news and predate the recent surge in virus infections caused by the Omicron variant. That already seems to have prompted a weakening of activity in December. And, although the economy has got better at coping with restrictions with each new wave, the possibility of tighter restrictions in January is further darkening the outlook for GDP."

The euro was priced at USD1.1270, firm from USD1.1267. Against the Japanese yen, the dollar was trading at JPY114.30, rising from JPY114.14.

Brent oil was quoted at USD74.14 a barrel on Wednesday morning, up from USD73.48 late Tuesday. Gold stood at USD1,786.23 an ounce, firm from USD1,785.40.

Wednesday's economic calendar has US GDP at 1330 GMT.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
7 Feb 2023 09:45

Syncona net asset value falls on "challenging" market, dollar weakness

(Alliance News) - Syncona Ltd on Tuesday reported a decline in its third quarter net asset value, noting a depreciating US dollar against sterling and a decline in the share price of investees.

Read more
7 Feb 2023 07:16

Syncona NAV falls in Q3

(Sharecast News) - Healthcare company Syncona said on Tuesday that net assets had fallen in the three months ended 31 December, principally due to the declining value of its quoted holdings and foreign exchange fluctuations.

Read more
25 Jan 2023 12:14

Life Science REIT lets second floor of Rolling Stock Yard in London

(Alliance News) - Life Science REIT PLC on Wednesday said it signed an agreement to lease the second floor of its Rolling Stock Yard asset near King's Cross, London, to a life science company backed by Syncona Ltd.

Read more
22 Dec 2022 08:04

Syncona investee Autolus sells more American shares

(Sharecast News) - Life science-focussed healthcare company Syncona said on Thursday that its portfolio company Autolus Therapeutics had announced that the underwriters of its public offering of American depositary shares (ADSs), which closed on 13 December, had partially exercised their option to purchase an additional 6,927,102 ADSs.

Read more
9 Dec 2022 10:36

Syncona portfolio firm hits 70% remission rate goal in leukaemia trial

(Alliance News) - Syncona Ltd on Friday said portfolio company Autolus Therapeutics PLC achieved the primary endpoint in the clinical trial of its treatment for acute lymphoblastic leukaemia.

Read more
9 Dec 2022 07:21

Syncona's Autolus leukemia treatment meets trial endpoint

(Sharecast News) - Syncona portfolio company Autolus Therapeutics announced that a phase 2 clinical trial in adult acute lymphoblastic leukemia (ALL) patients has met its primary endpoint at interim analysis.

Read more
6 Dec 2022 12:00

Syncona investee Achilles continues to progress cancer trials

(Alliance News) - Syncona Ltd on Tuesday noted the continued positive progress in lung cancer trials by its portfolio company.

Read more
1 Dec 2022 10:16

Syncona's Achilles says cancer treatment shows promise; seals buy

(Alliance News) - Syncona Ltd on Thursday noted a promising safety profile for a cancer therapy concocted by one investee, and separately announced the completion of an acquisition in the retinal gene therapy space.

Read more
29 Nov 2022 09:05

TOP NEWS: AstraZeneca to buy Neogene for cancer treatment

(Alliance News) - AstraZeneca PLC said it agreed to buy Neogene Therapeutics Inc for the treatment of cancer, as also noted by healthcare company Syncona Ltd on Tuesday.

Read more
29 Nov 2022 08:57

LONDON MARKET OPEN: Stocks up as protests in China deterred by police

(Alliance News) - The FSTE 100 opened in the green on Tuesday as investors were reassured that civil unrest in China would be short lived amid unyielding action by the authorities.

Read more
29 Nov 2022 07:50

LONDON BRIEFING: easyJet boasts "record bounce back" as loss narrows

(Alliance News) - Stocks in London were set to open slightly higher on Tuesday as unrest in the world's second largest economy continued.

Read more
17 Nov 2022 10:53

Syncona net assets rise in half year and outlines 10-year growth plans

(Alliance News) - Syncona Ltd on Thursday said net assets increased in the first half of its financial year, as it outlined plans to grow its net assets to GBP5 billion within the next 10 years.

Read more
17 Nov 2022 08:16

Syncona makes 'positive' operational and clinical progress in H1

(Sharecast News) - Healthcare company Syncona said on Thursday that it had delivered "positive operational and clinical progress" across its portfolio against a challenging macro backdrop in the six months ended 30 September.

Read more
15 Nov 2022 14:41

IN BRIEF: Syncona notes investee Freeline's third-quarter loss narrows

Syncona Ltd - London-based investor in healthcare companies - Notes third-quarter results of investee Freeline Therapeutics Holdings PLC. Freeline's pretax loss in the third quarter that ended September 30 narrows to USD65.9 million from USD105.7 million a year prior. Research & development expenses decrease to USD53.6 million from USD70.8 million, and total operating expenses fall by 27% to USD78.6 million from USD108.0 million. Freeline continues to make no revenue. Freeline enters a definitive agreement to sell its chemistry, manufacturing & control focused German subsidiary and related intellectual property for USD25 million, with the sale being subject to price adjustments.

Read more
10 Nov 2022 21:19

TRADING UPDATES: Zambeef expects profit jump; Mobile Streams wins deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.